ストックスクリーナーアプリを入手
98.37
1.33%
-1.33
アフターアワーズ：
98.24
-0.13
-0.13%
前日終値:
$99.70
開ける：
$99.57
24時間の取引高:
6.65M
Relative Volume:
0.66
時価総額：
$248.84B
収益：
$63.17B
当期純損益:
$12.15B
株価収益率:
54.65
EPS:
1.8
ネットキャッシュフロー:
$14.84B
1週間 パフォーマンス:
-1.01%
1か月 パフォーマンス:
-3.22%
6か月 パフォーマンス:
-20.54%
1年 パフォーマンス:
-9.77%
1日の値動き範囲:
$98.27
$99.57
1週間の範囲:
$98.27
$100.35
52週間の値動き範囲:
$94.48
$134.63
Merck Co Inc Stock (MRK) Company Profile
MRK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
98.37 | 248.84B | 63.17B | 12.15B | 14.84B | 4.77 |
|
LLY
Lilly Eli Co
|
773.84 | 695.93B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.73 | 380.78B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
143.34 | 345.11B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
176.20 | 311.37B | 55.53B | 5.12B | 15.62B | 2.88 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-12-04 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-11 | ダウングレード | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-03-11 | ダウングレード | Societe Generale | Hold → Sell |
| 2024-01-04 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Buy |
| 2023-10-27 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | アップグレード | UBS | Neutral → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Hold |
| 2023-04-13 | アップグレード | Citigroup | Neutral → Buy |
| 2023-03-28 | ダウングレード | Societe Generale | Buy → Hold |
| 2023-03-13 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 開始されました | Jefferies | Buy |
| 2023-02-22 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-10-10 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-09-14 | アップグレード | Berenberg | Hold → Buy |
| 2022-07-06 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 再開されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 開始されました | Goldman | Buy |
| 2021-12-16 | 開始されました | Daiwa Securities | Neutral |
| 2021-12-13 | ダウングレード | UBS | Buy → Neutral |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-12-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-11-29 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-01 | アップグレード | Argus | Hold → Buy |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-20 | ダウングレード | Argus | Buy → Hold |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-08-03 | アップグレード | Goldman | Neutral → Buy |
| 2020-06-12 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-08-16 | 開始されました | SVB Leerink | Outperform |
| 2019-07-03 | 開始されました | Mizuho | Buy |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-05-13 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 繰り返されました | Citigroup | Buy |
| 2018-10-09 | 再開されました | Guggenheim | Buy |
| 2018-04-23 | アップグレード | Goldman | Neutral → Buy |
| 2018-04-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-03-12 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-07 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2018-01-16 | アップグレード | SunTrust | Hold → Buy |
すべてを表示
Merck Co Inc (MRK) 最新ニュース
Is Merck & Co., Inc. (MRK) the Best Pharma Dividend Stock to Buy In 2024? - Yahoo Finance
5 Undervalued Stocks Positioned for a Breakout Year in 2025 - Investing.com
Merck & Co. Inc. stock outperforms competitors despite losses on the day - MarketWatch
Merck & Co. Inc. (MRK): Billionaire D.E. Shaw Is Bullish On This Stock Right Now - Insider Monkey
Will Weakness in Merck & Co., Inc.'s (NYSE:MRK) Stock Prove Temporary Given Strong Fundamentals? - Yahoo Finance
Merck & Co., Inc. (NYSE:MRK) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Merck & Co. Inc. stock rises Tuesday, still underperforms market - MarketWatch
Merck strikes a $2B GLP-1 deal with Hansoh - BioWorld Online
Wildlife Health Market May See a Big Move | Merck, C.H. Boehringer Sohn - openPR
Merck to discontinue drug for bacterial infection - Reuters
Merck: A Low-Hanging Fruit To Pick (NYSE:MRK) - Seeking Alpha
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and MoreEli Lilly (NYSE:LLY) - Benzinga
Merck - Contract Pharma
Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows - AOL
Merck & Co., Inc. (NYSE:MRK) Trading Down 0.8%Time to Sell? - MarketBeat
Merck & Co Inc (MRK) Stock Price, Trades & News - GuruFocus.com
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know - MSN
Merck: LM-299 antibody agreement finalized - Marketscreener.com
BMO cuts rating on Merck and Biogen, on lack of near term catalyst - Investing.com
Investing in Merck (NYSE:MRK) three years ago would have delivered you a 43% gain - Yahoo Finance
Merck & Co., Inc. (NYSE:MRK) Rating Lowered to "Market Perform" at BMO Capital Markets - MarketBeat
Merck’s doravirine/islatravir combo yields positive results in Phase 3 HIV-1 trials - World Pharmaceutical Frontiers
Merck secures global rights to novel cancer therapy - Investing.com
Is Merck & Co. (MRK) a Cheap NYSE Stock to Invest in Now? - Insider Monkey
Merck & Co buoyed by Phase III results with HIV tablet - The Pharma Letter
Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet - Simply Wall St
Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody - Business Wire
Analyst recommendations: Fedex, Merck, Nike, Coinbase, Tesla... - Marketscreener.com
Merck stock downgraded by BMO amid Gardasil, Keytruda concerns - Investing.com
Merck & Co Inc (MRK) DCF Valuation: Is The Stock Undervalued? - The Acquirer's Multiple
Merck & Co. Inc. stock outperforms competitors on strong trading day - MarketWatch
Merck & Co., Inc. (NYSE:MRK) Shares Up 0.5%What's Next? - MarketBeat
Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials - Benzinga
Merck & Co (MRK) technical analysisMerck & Co (NYSE:MRK), Hansoh Pharmaceutical Gr (OTC:HNSPF) - Benzinga
Merck: encouraging phase III results in HIV - Marketscreener.com
Merck's HIV treatment meets main goal in two late-stage studies - Reuters
Merck Buys $50 Million of Personalis Stock - Marketscreener.com
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna - Yahoo Finance
Merck shares reaffirm Market Perform rating on global in-licensing - Investing.com
Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time - Seeking Alpha
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug - Yahoo Finance
Merck’s RSV antibody could soon paddle into the rough waters of a crowded market - PharmaVoice
Merck's HIV-1 treatment meets efficacy in Phase 3 trials - Investing.com
Merck's HIV treatment meets main goal of two late-stage studies - Marketscreener.com
Merck stock slips after trial data for HIV drug (MRK:NYSE) - Seeking Alpha
Merck gets rights to Hansoh Pharma’s investigational diabetes drug - World Pharmaceutical Frontiers
Merck (MRK) Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir - StreetInsider.com
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection - Business Wire
Why Is Merck & Co., Inc. (MRK) Among the Best Dividend Stocks to Invest In? - Insider Monkey
Merck snags Chinese obesity drug in nearly $2 billion deal - Fortune
Merck (MRK) Stock Moves -1.72%: What You Should Know - Yahoo Finance
Merck Co Inc (MRK) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
大文字化:
|
ボリューム (24 時間):